Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo, Courtney D; Pratz, Keith; Pullarkat, Vinod; Jonas, Brian A; Arellano, Martha; Becker, Pamela S; Frankfurt, Olga; Konopleva, Marina; Wei, Andrew H; Kantarjian, Hagop M; Xu, Tu; Hong, Wan-Jen; Chyla, Brenda; Potluri, Jalaja; Pollyea, Daniel A; Letai, Anthony.
; 2018 Oct 25.
Artigo em Inglês | MEDLINE | ID: mdl-30361262
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Activity of azacitidine in chronic myelomonocytic leukemia.
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.